A randomized, double-blind, placebo-controlled crossover trial of valacyclovir for suppression of HSV (herpes simplex virus) and HIV shedding in HIV-1, HSV-2 coinfected men who have sex with men (MSM)

Trial Profile

A randomized, double-blind, placebo-controlled crossover trial of valacyclovir for suppression of HSV (herpes simplex virus) and HIV shedding in HIV-1, HSV-2 coinfected men who have sex with men (MSM)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2010

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV-1 infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top